Phase I trial of procarbazine as a 5-day continuous infusion in children with central nervous system tumors.
Seven children with previously treated brain tumors were enrolled in a phase I trial of 5-day continuous-infusion procarbazine at 360, 480, and 638 mg/m2/day. Vitamin B6 levels were monitored. Myelosuppression was moderate though occasionally delayed, and nausea and vomiting were mild. At the highest dose level, a patient experienced severe psychosis that persisted for several weeks. From that dose-limiting toxicity and the degree of myelosuppression, the recommended dose for phase II trials in children is the same as for adults, 450 mg/m2/day.
van Eys
J
J
Department of Pediatrics, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston 77030.
Cangir
A
A
Pack
R
R
Baram
T
T
D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use*
D011344:Procarbazine